Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

We continue to see very strong performance in hypertension in China. In Japan ... And moving to slide nine, Kisqali continued to cement its leadership in metastatic breast cancer, and launched ...

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...

China, Germany and Japan. Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Cosentyx, Entresto, Kesimpta, ...

Regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China. Kisqali has been approved as a treatment for metastatic breast cancer (MBC) patients in 99 ...

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China. This media update contains forward-looking statements within the meaning of the United States ...